

# Aging Pathobiology and Therapeutics

## **Hormesis-Based Anti-Aging Strategies: The role of free radicals and antioxidants in neurodegenerative diseases**

### **Guest Editor:**

#### ***Prof. Vittorio Calabrese***

Department of Biomedical & Biotechnological Sciences, School of Medicine, University of Catania, Via Santa Sofia, Catania, Italy.

#### ***Prof. Angela Trovato***

Department of Biomedical & Biotechnological Sciences, School of Medicine, University of Catania, Via Santa Sofia, Catania, Italy.

#### ***Dr. Marialaura Ontario***

Department of Biomedical & Biotechnological Sciences, School of Medicine, University of Catania, Via Santa Sofia, Catania, Italy.

#### ***Dr. Sergio Modafferi***

Department of Biomedical & Biotechnological Sciences, School of Medicine, University of Catania, Via Santa Sofia, Catania, Italy.

#### ***Prof. Edward J. Calabrese***

Department of Environmental Health Sciences, Morrill I, N344, University of Massachusetts, Amherst, MA 01003, USA.

## Topic: Hormesis-Based Anti-Aging Strategies: The role of free radicals and antioxidants in neurodegenerative diseases

GUEST EDITOR



### VITTORIO CALABRESE

Department of Biomedical & Biotechnological Sciences, School of Medicine, University of Catania, Via Santa Sofia, Catania, Italy.

Email: calabres@unict.it

Website: <http://www.biometec.unict.it/docenti/vittorio.calabrese>



### ANGELA TROVATO

Department of Biomedical & Biotechnological Sciences, School of Medicine, University of Catania, Via Santa Sofia, Catania, Italy.

Email: trovato@unict.it





## MARIALAURA ONTARIO

Department of Biomedical & Biotechnological Sciences, School of Medicine, University of Catania, Via Santa Sofia, Catania, Italy.

Email: marialaura.ontario@ontariosrl.it



## SERGIO MODAFFERI

Department of Biomedical & Biotechnological Sciences, School of Medicine, University of Catania, Via Santa Sofia, Catania, Italy.

Email: sergio.modafferi@gmail.com



## EDWARD J CALABRESE

Department of Environmental Health Sciences, University of Massachusetts, Amherst, MA, USA.

Email: edwardc@schoolph.umass.edu

## **Topic: Hormesis-Based Anti-Aging Strategies: The role of free radicals and antioxidants in neurodegenerative diseases**

### EDITORIAL

Targeting reactive oxygen species (ROS) while maintaining cellular redox signaling is crucial in the development of redox active interventions in mitochondrial medicine as the origin of several prevailing diseases including chronic neurodegenerative diseases is linked to ROS imbalance and associated mitochondrial dysfunction. Consistent with this notion anti-aging medicine is conceptually defined as a medical speciality founded on the application of advanced medical and scientific technologies for the early detection, prevention, treatment, and reversal of age-related dysfunction, disorders, and diseases. It is a healthcare model promoting innovative research to prolong the healthy lifespan in humans. In the twentieth century, the population are losing their health and lives to cancer, heart disease and neurodegenerative disease. These diseases, known as the diseases of aging, have an impact on the healthcare budgets worldwide. If we really want to make an impact on healthcare in the world, we must focus on the degenerative diseases of aging. If we can slow aging, we can eliminate more than 50 per cent of all diseases. It is possible to alter this dreadful course by delaying, preventing or reversing the diseases associated with aging. Application of any therapy or modality that delivers very early prevention, detection, treatment or reversal of aging-related dysfunction and disease, thus enhancing the quality and extending the length of the human lifespan is the most important new model for healthcare for this new millennium. During ageing low grade inflammation develops, which contributes to the pathogenesis of age-related diseases. Emerging interest has recently focused on markers of oxidative stress and neuroinflammation in neurodegenerative disorders as abnormal redox homeostasis, oxidative stress and altered antioxidant systems have been considered important factors underlying the pathogenesis of major degenerative disorders, such as Parkinson's disease (PD) and Alzheimer's disease (AD). The body's antioxidant capacity decreases, and the excessive accumulation of ROS lead to many health problems, such as cardiovascular diseases, diabetes, cancer, neurodegenerative diseases and so on. Basal levels of oxidants are indispensable for redox signaling to produce adaptive cellular responses such as vitagenes linked to cell survival, but at higher levels are detrimental to cells, contributing to aging and to the

pathogenesis of numerous age-related diseases. Altered expression of genes related to oxidative stress, oxidative damage to DNA, protein and lipids, as well as alterations in the redox state act synergistically, and contribute to the course of major age-related diseases. However, the concept that low levels of stress can induce responses that may be protective against the pathogenic processes is a frontier area of neurobiological research focal to understanding and developing therapeutic approaches to neurodegenerative pathologies. This special Issue want introduce and elucidate i the concept of cellular stress response and hormesis and its applications to the field of neuroprotection. Hormetic mechanisms are reviewed as possibility of targeted therapeutic manipulation in a cell-, tissue- and/or pathway-specific manner at appropriate points in the AD and PD disease processes. We aim to address and propose the potential therapeutic utility of nutritional polyphenols, in particular those with high potential in Nrf2 activation, inhibition of Keap1-Nrf2 protein–protein interaction and degradation as substantial regulators of the Nrf2 related pathway. Nutritional polyphenols are considered as potential pharmacological modulators of neuroinflammation and activators of the Keap1/Nfr2/ARE pathway as a rationale for treating neurodegenerative disorders. Hence, emerging interest is focusing on the neuroprotective and anti-neuroinflammatory effects of herbal medicines for enhancing stress resilience and brain health in humans. Recent evidence demonstrates that mushroom polyphenols, olive oil polyphenols, sulphuraphane or saffron and its major constituents counteracts and neutralizes genetic and environmental stressors, particularly oxidative stress, mitochondrial dysfunction and neuroinflammation closely connected to brain disorders initiation and progression. Interestingly, these compounds, underlying the emerging principles of hermetic nutrition, can exert antioxidant or toxic effects depending on their endogenous concentration. According to the hormesis approach, they at low dose act as antioxidants in a wide range of brain diseases by upregulating Nrf2 signaling pathway and the expression of vitagenes, such as NAD(P)H-quinone oxidoreductase (NQO1), glutathione transferase (GT), GPx, heme oxygenase-1 (HO-1), sirtuin-1 (Sirt1) and thioredoxin (Trx) system which play an important role in the metabolism of reactive oxygen species (ROS), detoxification of xenobiotics and inhibition of neuronal death, by blocking ROS production and neurotoxic damage. Importantly, neuronal dysregulation of Nrf2 pathway can be a prominent cause of selective susceptibility under neuroinflammatory conditions due to the high vulnerability of brain cells to oxidative stress. Here we will discuss, general mechanisms targeting Nrf2/vitagene pathways for development of new therapeutical strategies to suppress oxidative stress and neuroinflammation and

consequently cognitive dysfunction, summarizing major neuroprotective and anti-neuroinflammatory properties as well as pharmacological perspectives in brain disorders.

## Topic: Hormesis-Based Anti-Aging Strategies: The role of free radicals and antioxidants in neurodegenerative diseases

### PARTICIPANTS

#### **HIROOMI TAMURA**

Faculty of Pharmacy, Keio University, 1-5-30 Shibako Minato-ku, Tokyo 105-8512, Japan.

#### **ABIOLA FOLAKEMI OLANIRAN**

Department of Food Science and Microbiology, College of Pure and Applied Sciences, Landmark University, P.M.B 1001, Omu-Aran, Nigeria.

#### **IVÁN A. GARCÍA-MONTALVO**

Division of Postgraduate Studies and Research, Tecnológico Nacional de México/Instituto Tecnológico de Oaxaca, Oaxaca City, Oaxaca, México.

#### **OLUBUKOLA H OYENIRAN**

Functional Foods, Nutraceuticals and Phytomedicine Unit, Department of Biochemistry, Federal University of Technology, Akure, Nigeria.

#### **SHIGEO OHTA**

Department of Neurology Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Bunkyo-ku, Tokyo, 113-8431, Japan.

#### **LUIS APAZA TICONA**

Organic Chemistry Unit, Department of Chemistry in Pharmaceutical Sciences, Faculty of Pharmacy, Universidad Complutense of Madrid, Plaza. Ramón y Cajal s/n, 28040, Madrid, Spain.

#### **STEVEN BRENNER**

Department of Neurology and Psychiatry, Saint Louis University, School of Medicine, Montelone Hall, 1438 South Grand Boulevard, Saint Louis, Missouri 63104, United States of America.

#### **LEILA CHEKIR-GHEDIRA**

Laboratoire de Biologie Moléculaire et Cellulaire, Faculté de Médecine Dentaire de Monastir, Université de Monastir, Monastir, Tunisia.

#### **JAN MASAN**

University of St. Cyril and Methodius in Trnava, Slovakia.

**CATIA SCASSELLATI**

Biological Psychiatry Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

**MARINA G MAKLETSOVA**

Department of Biology and General Pathology, Don State Technical University, Gagarin Square 1, Rostov-on-Don 344011, Russia.

**ANNE POLJAK**

Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Sydney, NSW 2052, Australia.

**JOHNSON O OLADELE**

Department of Chemical Sciences, Biochemistry Unit, Kings University, Ode-Omu, Nigeria.



## **Topic: Hormesis-Based Anti-Aging Strategies: The role of free radicals and antioxidants in neurodegenerative diseases**

### CONTENTS

*1 MOLECULAR HYDROGEN MAY ACTIVATE THE TRANSCRIPTION FACTOR NRF2 TO ALLEVIATE OXIDATIVE STRESS THROUGH THE HYDROGEN-TARGETED PORPHYRIN*

Shigeo Ohta

*Aging Pathobiol Ther*, 2023, 5(1): 25-32. doi: 10.31491/APT.2023.03.104.

# Molecular hydrogen may activate the transcription factor Nrf2 to alleviate oxidative stress through the hydrogen-targeted porphyrin

Shigeo Ohta<sup>a, b, \*</sup>

<sup>a</sup> Department of Neurology Medicine, Juntendo University, Graduate School of Medicine, Tokyo, 113-8421, Japan.

<sup>b</sup> Department of Cell Biology, Graduate School of Medicine, Nippon Medical University, Tokyo, 113-8602, Japan.

This article belongs to the Special Issue: [Hormesis-Based Anti-Aging Strategies: The role of free radicals and antioxidants in neurodegenerative diseases](#)

## Abstract

Oxidative stress is one of the major causes of most age-dependent neurodegenerative disorders. Neurons accumulate oxidative damage over time due to post-mitotic cells. Thus, modulation of oxidative stress is essential to overcome these disorders. Molecular hydrogen (H<sub>2</sub>) has great potential for treating various diseases and improving quality of life by exerting multiple functions including anti-oxidation, anti-inflammation, and energy metabolism promotion. Among these functions, H<sub>2</sub> activates a transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) to enhance the transcription of transcribe a broad range of anti-stress enzymes, including antioxidant enzymes. There was an elusive contradiction between H<sub>2</sub> and Nrf2 because Nrf2 is activated in response to oxidative stress, whereas H<sub>2</sub> has a reducing potential. The target molecule for H<sub>2</sub> has recently been identified as the oxidized form of Fe-porphyrin conjugated with the -OH group (PrP-Fe(III)-OH). As the initial step, the hydroxyl radical (•OH) oxidizes heme (PrP-Fe(II)) to form PrP-Fe(III)-OH. Then, H<sub>2</sub> reacts with PrP-Fe(III)-OH to produce PrP-Fe(III)-H and H<sub>2</sub>O. In turn, Fe(III) with H has the potential to act as an electrophile to oxidize Kelch-like ECH-associated protein 1 (Keap1), resulting in activating Nrf2. Thus, when the original highly damaging electrophilicity of •OH is buffered by H<sub>2</sub> and its target porphyrin, the electrophilicity provided by •OH can indirectly activate Nrf2 to reduce oxidative stress. Even without lowering the dosage, the effect of alleviated potent is considered to be hormesis-like. This “Therapeutic Brief” propose that the alleviated oxidative potent of •OH functions to activate Nrf2 as hormesis-like.

**Keywords:** Hematin, hydroxyl radical, molecular hydrogen, Nrf2, oxidative stress, porphyrin

## Introduction

Molecular hydrogen (dihydrogen; H<sub>2</sub>) is an inert molecule in the absence of a catalyst. It has long been believed that H<sub>2</sub> has no biological function in mammalian cells because mammals lack the genes encoding hydrogenases that catalyze reactions involving H<sub>2</sub> [1, 2]. In 2007, this

concept was overturned by publishing the article entitled “Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals” [3]. This paper served as a trigger for the initiation of a new field of “hydrogen medicine and agriculture” [4, 5]. Subsequently, in addition to its antioxidant action, H<sub>2</sub> has been revealed to exert multiple functions such as anti-inflammatory, anti-allergic, anti-cell death, and metabolic stimulating effects by modulating various intracellular signal transductions [5, 6]. H<sub>2</sub> has no adverse effects, leading to extensive clinical studies for various diseases [5, 6]. In addition, H<sub>2</sub> not only improves patients with various diseases, but also supports the quality of life (QOL) of healthy people in various fields such as healthcare, sports, and beauty [5]. In 2014, the US Food Drug Administration (FDA) approved H<sub>2</sub> as generally recognized as safe (GRAS), allowing hydrogen-infused water to be marketed as a drink. In 2016, H<sub>2</sub> gas

\* Corresponding author: Shigeo Ohta

Mailing address: Department of Neurology Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

Email: ohta@nms.ac.jp

Received: 30 December 2022 / Revised: 31 January 2023

Accepted: 06 March 2023 / Published: 29 March 2023

inhalation therapy was approved by the Japanese government as an advanced treatment for post-cardiac arrest syndrome [7]. Furthermore, H<sub>2</sub> is beneficial not only to animals and humans but also to higher plants. Therefore, H<sub>2</sub> can have a strong impact on agriculture [8]. However, the molecular mechanism by which H<sub>2</sub> exerts multiple functions remained unclear. The current Therapeutic Brief will discuss and propose a molecular mechanism by which H<sub>2</sub> with the hydrogen-targeted porphyrin activates the transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) to alleviate oxidative stress, suggesting a hormesis-like effect.

### H<sub>2</sub> selectively reacts with hydroxyl radicals in living cells

Oxidative stress is derived by excessive generation of reactive oxygen species (ROS) such as superoxide anion radical ( $\bullet\text{O}_2^-$ ), hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), nitric oxide (NO), and hydroxyl radical ( $\bullet\text{OH}$ ) [9-10]. As neurons are post-mitotic cells, neurons accumulate oxidative damage over many years. However, ROS such as H<sub>2</sub>O<sub>2</sub> and  $\bullet\text{O}_2^-$  and NO play important physiological roles in signaling cascades and biological processes such as cell proliferation, differentiation, apoptosis, and immunomodulation [11-14], and thus, excessive antioxidant intake is not beneficial and induces mortality as published [15, 16].

Molecular hydrogen (H<sub>2</sub>) selectively reduces highly toxic ROS,  $\bullet\text{OH}$  and peroxyxynitrite (ONOO<sup>-</sup>), but neither  $\bullet\text{O}_2^-$ , H<sub>2</sub>O<sub>2</sub>, nor NO [3]. In cell culture experiments, H<sub>2</sub> decreased the fluorescence signal of 3'-p-(hydroxyphenyl) fluorescein (HPF) when oxidative stress was induced in various ways [3]. HPF is an intracellular marker for  $\bullet\text{OH}$  [17, 18]. Decrease in this fluorescent signal by H<sub>2</sub> was not only observed in cultured cells, but also in various tissues as shown in testicular radioprotection [19], hematopoietic stem cell damage by total body irradiation [20], and hyperoxia in cultured cells [21], lung hypoxia/reoxygenation [22], retinal ischemia-reperfusion [23], and retinal sonication [24].

H<sub>2</sub> can be infused into water (hydrogen water) up to a maximum of 0.8 mM at atmospheric pressure. After drinking H<sub>2</sub> water or inhaling H<sub>2</sub> gas, measuring the H<sub>2</sub> content revealed that H<sub>2</sub> is consumed in the human body [25, 26]. Deuterium gas (D<sub>2</sub>) was used in rats as a metabolic tracer to monitor D<sub>2</sub> oxidation, indicating that molecular hydrogen is indeed oxidized *in vivo* [27].

Thus, H<sub>2</sub> was confirmed to decrease cellular  $\bullet\text{OH}$  in a variety of ways across cell types and tissues although  $\bullet\text{OH}$  is the most oxidative molecule to damage the cell components in a chaotic manner [10].

By the way, in homogeneous aqueous kinetics, the reaction rate of  $\bullet\text{OH}$  with H<sub>2</sub> is much slower (the kinetic rate is  $0.35 \times 10^{-8} \text{ M}^{-1}\text{s}^{-1}$ ) than those with other antioxidants [28]. For example,  $\bullet\text{OH}$  reacts with glucose and glutathione with kinetic rates ( $15 \times 10^{-8} \text{ M}^{-1}\text{s}^{-1}$ ), and ( $230 \times 10^{-8} \text{ M}^{-1}\text{s}^{-1}$ ), respectively [29]. The other biomolecules also react with  $\bullet\text{OH}$  much faster than H<sub>2</sub>. The contradiction between

homogeneous aqueous solutions and living organisms has been debated for a long time.

Although H<sub>2</sub> cannot react with most molecules without a metal catalyst, effective amounts of metals such as Cu, Fe, Ni, and Pt are unlikely to be present in living cells. In addition, there is no report indicating the discovery of an organo-catalyst for H<sub>2</sub>. Despite extensive worldwide research, it was hard to discover a catalyst that facilitates the reaction of H<sub>2</sub> with  $\bullet\text{OH}$ . An H<sub>2</sub>-target molecule as described below has recently been identified, providing a clue to explain the underlying contradiction of H<sub>2</sub>.

### Aging is associated with an increased incidence of neurodegenerative diseases

Aging is associated with an increased incidence of neurodegenerative disorders. This is because neurons accumulate oxidative damage due to post-mitotic cells over a long period [30]. Oxidative stress is one of the leading causes of most neurodegenerative disorders [31, 32]. Several animal studies indicate that H<sub>2</sub>-treatment is potentially applicable to alleviate neurodegenerative disorders and improve the quality of life in the elderly [33-37]. Thus, H<sub>2</sub> is expected to ameliorate aging-related neurodegeneration. In particular, overcoming Alzheimer's disease (AD) is one of the most important challenges in the world's aging society [38].

It has been shown that drinking H<sub>2</sub> water reduces oxidative stress and ameliorated cognitive deficits in AD model mice [39]. Subsequently, a randomized, placebo-controlled, double-blind clinical trial was conducted on subjects with mild cognitive impairment (MCI), who drank 0.6 mM H<sub>2</sub> water (approximately 300 ml per day) for 1 year [39]. A sub-analysis showed that subjects with the apolipoprotein E (APOE4) genotype, a well-known genetic factor for AD [40, 41], were significantly improved. Improvement was assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), one of the most reliable ways to assess cognition [42, 43].

H<sub>2</sub> inhalation has been applied in several clinical areas [5, 7, 44-46]. The most important feature of H<sub>2</sub> gas inhalation therapy is that it is non-cytotoxic and safe for humans, as approved in Phase I clinical trial [47].

A patient with severe Alzheimer's continued to inhale 3% hydrogen gas twice for one hour a day for two years. Diffusion tensor imaging (DTI) [48, 49] then visualized the activation of neurons of the patient, and urinary and fecal incontinence was improved [38]. This case report is of value even for a single case, as it is commonly understood that patients with severe AD are irreversible [38].

### H<sub>2</sub> activates Nrf2 to function to reduce oxidative stress

Nrf2 transcribes the genes encoding several antioxidant enzymes to protect cells against oxidative stress [50-51]. Moreover, Nrf2 contributes not only to the reduction of

oxidative stress, but also to widespread fields, including toxicology [52], oncology [53], inflammation [54], ischemia stroke [55], and the aging process [56]. Nrf2's targets are the genes encoding NAD (P) H quinone oxidoreductase 1 (Nqo1), thioredoxin, reductase 1 (TXNRD1), heme oxygenase-1 (HO-1), glutathione S-transferase (GST), and so on [50-51]. Nrf2 is maintained in an inactive form in the cytosol when it forms a complex with the Kelch-like ECH-associated protein 1 (Keap1). Upon oxidation of the essential cysteine residues of Keap1 by electrophiles, Nrf2 is released from Keap1 and then translocated into the nucleus, enabling the transcriptions [50-51].

H<sub>2</sub> can induce the activity of Nrf2, as shown in many publications. In Nrf2 knockout mice, the effects of H<sub>2</sub> were at least partially attenuated, in protecting various cells and tissues in response to various stressors [57]. These findings are consistent with subsequent publications that Nrf2-activation is one of the antioxidant effects of H<sub>2</sub> [58-69]. Therefore, it is concluded that the activation of Nrf2 is involved in one of the H<sub>2</sub> functions.

As a molecular mechanism, it is unlikely that H<sub>2</sub> directly influences Nrf2. H<sub>2</sub> must indirectly activate Nrf2 through multiple steps. One idea was proposed that H<sub>2</sub> enhances mitochondrial respiratory activity to generate excess ROS, which in turn oxidizes intracellular Keap1 to release Nrf2 [70]. Alternatively, H<sub>2</sub> opens mitochondria-(ATP) K<sup>+</sup> channels [71, 72] to induce ROS [73]. However, although there is no doubt that H<sub>2</sub> activates Nrf2, there is no direct evidence that mitochondria-derived ROS can oxidize the residues of cytosolic Keap1. Moreover, an elusive contradiction exists between Nrf2 activation and H<sub>2</sub>; activation of Nrf2 requires Keap1 oxidation, whereas H<sub>2</sub> has a reducing potential.

### Target discovery of hydrogen molecules

A break-through paper entitled "Fe-porphyrins: redox-related biosensors of molecular hydrogen" has recently been published [74], showing that the molecular target/biosensor for H<sub>2</sub> is the oxidized form of Fe-porphyrins (designate "hematin"). This paper has shown the discovery that addresses the fundamental questions about the mechanisms in which H<sub>2</sub> is involved.


Hematin is an oxidized form of Fe(III)-containing porphyrin (PrP) converted from Fe(II)-containing porphyrin (heme) [75, 76]. This breakthrough paper showed a novel reaction showing that H<sub>2</sub> replaces the hydroxy group (-OH) conjugated to hematin Fe(III) with the hydrogen group (-H). The atom H of this -H group should behave as a hydride (H<sup>-</sup>) and, due to its high reactivity, •OH was rapidly converted to H<sub>2</sub>O by this catalyst (Figure 1).

Thus, heme (PrP-Fe(II)) has been shown to act as a catalyst for the following reaction (Figure 1).

- (1) PrP-Fe(II) + •OH → PrP-Fe(III)-OH
- (2) PrP-Fe(III)-OH + H<sub>2</sub> → PrP-Fe(III)-H + H<sub>2</sub>O
- (3) PrP-Fe(III)-H + •OH → PrP-Fe(II) + H<sub>2</sub>O

The overall equation (4) indicates that heme (PrP-Fe(II))

catalyzed the following reactions:




As noted above, the unresolved discrepancy between aqueous and live-cell reactions can be explained by the catalytic reaction according to the above equations (2) and (3).

At the same time, H<sub>2</sub> can reduce the oxidized porphyrin with Fe(III) to restore heme, the reduced form of Fe(II).

### Proposal of a mechanism to elucidate the mechanism by which reducing H<sub>2</sub> activates Nrf2

Porphyrins are distributed everywhere inside and outside the living cells in the body. Heme is present in hemoglobin in the blood and myoglobin in muscles and is responsible



**Figure 1.** Fe-porphyrin catalyzes the reaction of H<sub>2</sub> with the hydroxyl radical.

(Equation 1) PrP-Fe(II) + •OH → PrP-Fe(III)-OH

(Equation 2) PrP-Fe(III)-OH + H<sub>2</sub> → PrP-Fe(III)-H + H<sub>2</sub>O


(Equation 3) PrP-Fe(III)-H + •OH → PrP-Fe(II) + H<sub>2</sub>O

The formal name of Hematin PrP-Fe(III)-OH is ferriprotoporphyryn IX hydroxide.

for delivering molecular oxygen (O<sub>2</sub>) throughout the body [77]. Thus, heme is frequently exposed to O<sub>2</sub> or H<sub>2</sub>O<sub>2</sub>, and thus, Fe(II) of heme can frequently catalyze the formation of •OH by the Fenton reaction or its mimic reactions [78-80]. Porphyrins are located as cytochromes in the electron transport chain of the mitochondrial inner membrane, and play a role in electron transport by converting Fe(II) to/from Fe(III) [81]. In the intracellular cytosol, the antioxidant enzymes such as catalase [82] and peroxidase [83], P450 [84], and nitric oxide (NO) synthase [85] have porphyrins as an essential component [86]. These porphyrins

with Fe(II)/(III) act as mediators of redox reactions and are subject to oxidative stress.

Hematin (PrP-Fe(III)-OH) is converted from hemin (PrP-



**Figure 2.** Fe(III) in hydride hematin can serve as an electrophile to oxidize the residues of Keap1.

Hematin and heme can mutually be converted, and heme is known to activate Nrf2 by oxidizing Keap1.

Fe(III) of heme is electrophilic to activate Nrf2. Fe(III)-H may be more electrophilic than Fe(III)-Cl to efficiently oxidize Keap1, resulting in activating Nrf2.

The formal name of Hemin PrP-Fe(III) is ferriprotoporphyrin IX chloride.

Fe(III)-Cl) [87, 88]. Notably, heme (PrP-Fe(III)-Cl) activate Nrf2 [89-91] (Figure 2). The Fe(III) of heme probably functions as an electrophile, oxidizing the residues of Keap1 and activating Nrf2. The electronegativities of H and Cl are 2.2 and 3.16, respectively. Thus, Fe(III) containing H should be more electrophilic than Fe(III) containing Cl, and may be able to oxidize Keap1 more efficiently according to the equation of  $\text{PrP-Fe(III)-H} + e^- \rightarrow \text{PrP-Fe(II)} + 1/2 \text{H}_2$  (Figure 2).

As mentioned in the above equation (1)  $\text{PrP-Fe(II)} + \bullet\text{OH} \rightarrow \text{PrP-Fe(III)-OH}$ , hematin (PrP-Fe(III)-OH) was originally formed by oxidizing heme (PrP-Fe(II)) by  $\bullet\text{OH}$ .  $\bullet\text{OH}$  is the most oxidative molecule to damage biomolecules indiscriminately [10], but the strong electrophilicity of  $\bullet\text{OH}$  can be buffered in the presence of  $\text{H}_2$  and Fe-PrP, and resultant electrophilicity in Fe-PrP can contribute to activating Nrf2, resulting in reducing oxidative stress.

Hormesis is a term used by toxicologists to refer to a biphasic dose response to an environmental agent characterized by a low-dose stimulation or beneficial effect and a high-dose inhibitory or toxic effect [92] or defined as the paradoxical beneficial effects of low-dose stressors, which can be better defined as the biphasic dose-effect or time-

effect relationship for any substance [93].

$\bullet\text{OH}$  is the most oxidative molecule that caused damage to biomolecules [10], but, the strong electrophilicity of  $\bullet\text{OH}$  can be alleviated through stepwise reactions in the presence of  $\text{H}_2$  and porphyrin.

Lowering the concentration of a toxic substance is reducing its toxicity. It is proposed that even without lowering the dosage, the effect of alleviated strong potent is considered to be hormesis-like.

Once the original strong electrophilicity of  $\bullet\text{OH}$  is transferred to PrP-Fe(III)-OH and PrP-Fe(III)-H, it is possible that the alleviated oxidative potent contributes to the activation of Nrf2 as a hormesis-like effect.

The current proposal needs to be examined in more detail in the future.

## Conclusion

$\text{H}_2$  acts as a therapeutic antioxidant [3] and activates Nrf2, which transcribes antioxidant enzymes to reduce oxidative stress and protected cells against various stresses. There was an unresolved contradiction between  $\text{H}_2$ 's reductive property and Nrf2's requirement of oxidative stress for its activation. The target molecule for  $\text{H}_2$  has recently been identified as the oxidized form of Fe-porphyrin conjugated with the OH group (PrP-Fe(III)-OH) [74].  $\text{H}_2$  and the  $\text{H}_2$ -targeting porphyrin can buffer the highly oxidizing electrophilicity of  $\bullet\text{OH}$ . When the original  $\bullet\text{OH}$ 's oxidative and harmful electrophilicity is alleviated, the resultant electrophilic potent may contribute to the activation of Nrf2 as a hormesis-like effect.

## Declarations

**Authors' contributions:** The author contributed solely to the article.

**Availability of data and materials:** Not applicable.

**Conflicts of interest:** The author is the director of  $\text{H}_2$  WATER JAPAN, Inc., (Tokyo, Japan) and  $\text{H}_2$  Global Group (Ostrava, Czech Republic), companies involved in  $\text{H}_2$ .

**Ethical approval and informed consent statement:** Not applicable.

**Consent for publication:** Not applicable.

## References

1. Yagi T, & Higuchi Y. Studies on hydrogenase. *Proc Jpn Acad Ser B Phys Biol Sci*, 2013, 89(1): 16-33. [Crossref]
2. Hansen M, & Perner M. Hydrogenase Gene Distribution and  $\text{H}_2$  Consumption Ability within the Thiomicrospira Lineage. *Front Microbiol*, 2016, 7: 99. [Crossref]
3. Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K, *et al*. Hydrogen acts as a therapeutic



- antioxidant by selectively reducing cytotoxic oxygen radicals. *Nat Med*, 2007, 13(6): 688-694. [[Crossref](#)]
4. Ohta S. Molecular hydrogen as a preventive and therapeutic medical gas: initiation, development and potential of hydrogen medicine. *Pharmacol Ther*, 2014, 144(1): 1-11. [[Crossref](#)]
  5. Ohta S. Development of Hydrogen Medicine and Biology: Potential for Various Applications in Diverse Fields. *Curr Pharm Des*, 2021, 27(5): 583-584. [[Crossref](#)]
  6. Nicolson GL, de Mattos GF, Settineri R, Costa C, Ellithorpe R, Rosenblatt S, *et al*. Clinical Effects of Hydrogen Administration: From Animal and Human Diseases to Exercise Medicine. *International Journal of Clinical Medicine*, 2016, 07(01): 32-76. [[Crossref](#)]
  7. Katsumata Y, Sano F, Abe T, Tamura T, Fujisawa T, Shiraishi Y, *et al*. The Effects of Hydrogen Gas Inhalation on Adverse Left Ventricular Remodeling After Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction - First Pilot Study in Humans. *Circ J*, 2017, 81(7): 940-947. [[Crossref](#)]
  8. Li C, Gong T, Bian B, & Liao W. Roles of hydrogen gas in plants: a review. *Funct Plant Biol*, 2018, 45(8): 783-792. [[Crossref](#)]
  9. Turrens JF. Mitochondrial formation of reactive oxygen species. *J Physiol*, 2003, 552(Pt 2): 335-344. [[Crossref](#)]
  10. Chou DS, Lee JJ, Hsiao G, Hsieh CY, Tsai YJ, Chen TF, *et al*. Baicalein induction of hydroxyl radical formation via 12-lipoxygenase in human platelets: an ESR study. *J Agric Food Chem*, 2007, 55(3): 649-655. [[Crossref](#)]
  11. Josephson RA, Silverman HS, Lakatta EG, Stern MD, & Zweier JL. Study of the mechanisms of hydrogen peroxide and hydroxyl free radical-induced cellular injury and calcium overload in cardiac myocytes. *J Biol Chem*, 1991, 266(4): 2354-2361.
  12. Papa S, & Skulachev VP. Reactive oxygen species, mitochondria, apoptosis and aging. *Mol Cell Biochem*, 1997, 174(1-2): 305-319.
  13. Sauer H, Wartenberg M, & Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. *Cell Physiol Biochem*, 2001, 11(4): 173-186. [[Crossref](#)]
  14. Thomas DT, DelCimmino NR, Flack KD, Stec DE, & Hinds TD, Jr. Reactive Oxygen Species (ROS) and Antioxidants as Immunomodulators in Exercise: Implications for Heme Oxygenase and Bilirubin. *Antioxidants (Basel)*, 2022, 11(2). [[Crossref](#)]
  15. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, & Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. *JAMA*, 2007, 297(8): 842-857. [[Crossref](#)]
  16. Hackam DG. Review: antioxidant supplements for primary and secondary prevention do not decrease mortality. *ACPJ Club*, 2007, 147(1): 4.
  17. Setsukinai K, Urano Y, Kakinuma K, Majima HJ, & Nagano T. Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. *J Biol Chem*, 2003, 278(5): 3170-3175. [[Crossref](#)]
  18. Tomizawa S, Imai H, Tsukada S, Simizu T, Honda F, Nakamura M, *et al*. The detection and quantification of highly reactive oxygen species using the novel HPF fluorescence probe in a rat model of focal cerebral ischemia. *Neurosci Res*, 2005, 53(3): 304-313. [[Crossref](#)]
  19. Chuai Y, Shen J, Qian L, Wang Y, Huang Y, Gao F, *et al*. Hydrogen-rich saline protects spermatogenesis and hematopoiesis in irradiated BALB/c mice. *Med Sci Monit*, 2012, 18(3): Br89-94. [[Crossref](#)]
  20. Chuai Y, Qian L, Sun X, & Cai J. Molecular hydrogen and radiation protection. *Free Radic Res*, 2012, 46(9): 1061-1067. [[Crossref](#)]
  21. Yu J, Yu Q, Liu Y, Zhang R, & Xue L. Hydrogen gas alleviates oxygen toxicity by reducing hydroxyl radical levels in PC12 cells. *PLoS One*, 2017, 12(3): e0173645. [[Crossref](#)]
  22. Chen M, Zhang J, Chen Y, Qiu Y, Luo Z, Zhao S, *et al*. Hydrogen protects lung from hypoxia/re-oxygenation injury by reducing hydroxyl radical production and inhibiting inflammatory responses. *Sci Rep*, 2018, 8(1): 8004. [[Crossref](#)]
  23. Oharazawa H, Igarashi T, Yokota T, Fujii H, Suzuki H, Machide M, *et al*. Protection of the retina by rapid diffusion of hydrogen: administration of hydrogen-loaded eye drops in retinal ischemia-reperfusion injury. *Invest Ophthalmol Vis Sci*, 2010, 51(1): 487-492. [[Crossref](#)]
  24. Igarashi T, Ohsawa I, Kobayashi M, Igarashi T, Suzuki H, Iketani M, *et al*. Hydrogen prevents corneal endothelial damage in phacoemulsification cataract surgery. *Sci Rep*, 2016, 6: 31190. [[Crossref](#)]
  25. Shimouchi A, Nose K, Shirai M, & Kondo T. Estimation of molecular hydrogen consumption in the human whole body after the ingestion of hydrogen-rich water. *Adv Exp Med Biol*, 2012, 737: 245-250. [[Crossref](#)]
  26. Shimouchi A, Nose K, Mizukami T, Che DC, & Shirai M. Molecular hydrogen consumption in the human body during the inhalation of hydrogen gas. *Adv Exp Med Biol*, 2013, 789: 315-321. [[Crossref](#)]
  27. Hyspler R, Ticha A, Schierbeek H, Galkin A, & Zadak Z. The Evaluation and Quantitation of Dihydrogen Metabolism Using Deuterium Isotope in Rats. *PLoS One*, 2015, 10(6): e0130687. [[Crossref](#)]
  28. Buxton GV, Greenstock, C.L., Helman, W.P., Ross, A.B. Critical review of rate constants for reactions of hydrated electrons, hydrogen atoms and hydroxyl radicals ( $\cdot\text{OH}/\cdot\text{O}^-$ ) in aqueous solution. *J Phys Chem Ref Data*, 1988, 17(2): 513-886. [[Crossref](#)]
  29. Wood KC, & Gladwin MT. The hydrogen highway to reperfusion therapy. *Nat Med*, 2007, 13(6): 673-674. [[Crossref](#)]
  30. Espinós C, Galindo MI, García-Gimeno MA, Ibáñez-Cabellos JS, Martínez-Rubio D, Millán JM, *et al*. Oxidative Stress, a Crossroad Between Rare Diseases and Neurodegeneration. *Antioxidants (Basel)*, 2020, 9(4). [[Crossref](#)]
  31. Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, & Radi E. Mitochondria, oxidative stress and neurodegeneration. *J Neurol Sci*, 2012, 322(1-2): 254-262. [[Crossref](#)]
  32. Chalke SD, & Kale PP. Combinational Approaches Target-

- ing Neurodegeneration, Oxidative Stress, and Inflammation in the Treatment of Diabetic Retinopathy. *Curr Drug Targets*, 2021, 22(16): 1810-1824. [Crossref]
33. Nagata K, Nakashima-Kamimura N, Mikami T, Ohsawa I, & Ohta S. Consumption of molecular hydrogen prevents the stress-induced impairments in hippocampus-dependent learning tasks during chronic physical restraint in mice. *Neuropsychopharmacology*, 2009, 34(2): 501-508. [Crossref]
  34. Li J, Wang C, Zhang JH, Cai JM, Cao YP, & Sun XJ. Hydrogen-rich saline improves memory function in a rat model of amyloid-beta-induced Alzheimer's disease by reduction of oxidative stress. *Brain Res*, 2010, 1328: 152-161. [Crossref]
  35. Tan X, Shen F, Dong WL, Yang Y, & Chen G. The role of hydrogen in Alzheimer's disease. *Med Gas Res*, 2018, 8(4): 176-180. [Crossref]
  36. Zheng ZG, Sun WZ, Hu JY, Jie ZJ, Xu JF, Cao J, et al. Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial. *Respir Res*, 2021, 22(1): 149. [Crossref]
  37. Lin YT, Shi QQ, Zhang L, Yue CP, He ZJ, Li XX, et al. Hydrogen-rich water ameliorates neuropathological impairments in a mouse model of Alzheimer's disease through reducing neuroinflammation and modulating intestinal microbiota. *Neural Regen Res*, 2022, 17(2): 409-417. [Crossref]
  38. Ono H, Nishijima Y, Sakamoto M, Kitamura S, Naitoh Y, Suzuki K, et al. Long-Term Inhalation of Hydrogen Gas for Patients with Advanced Alzheimer's Disease: A Case Report Showing Improvement in Fecal Incontinence. *Med Res Arch*, 2022, 10(7). [Crossref]
  39. Nishimaki K, Asada T, Ohsawa I, Nakajima E, Ikejima C, Yokota T, et al. Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment. *Curr Alzheimer Res*, 2018, 15(5): 482-492. [Crossref]
  40. Bookheimer S, & Burggren A. APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. *Annu Rev Clin Psychol*, 2009, 5: 343-362. [Crossref]
  41. Uddin MS, Kabir MT, Al Mamun A, Abdel-Daim MM, Barreto GE, & Ashraf GM. APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis. *Mol Neurobiol*, 2019, 56(4): 2450-2465. [Crossref]
  42. Grossberg GT, Schmitt FA, Meng X, Tekin S, & Olin J. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. *Am J Alzheimers Dis Other Dement*, 2010, 25(8): 627-633. [Crossref]
  43. Kueper JK, Speechley M, & Montero-Odasso M. The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review. *J Alzheimers Dis*, 2018, 63(2): 423-444. [Crossref]
  44. Ono H, Nishijima Y, Ohta S, Sakamoto M, Kinone K, Horikosi T, et al. Hydrogen Gas Inhalation Treatment in Acute Cerebral Infarction: A Randomized Controlled Clinical Study on Safety and Neuroprotection. *J Stroke Cerebrovasc Dis*, 2017, 26(11): 2587-2594. [Crossref]
  45. Botek M, Krejčí J, Valenta M, McKune A, Sládečková B, Konečný P, et al. Molecular Hydrogen Positively Affects Physical and Respiratory Function in Acute Post-COVID-19 Patients: A New Perspective in Rehabilitation. *Int J Environ Res Public Health*, 2022, 19(4). [Crossref]
  46. Pluta R, Januszewski S, & Czuczwar SJ. Molecular Hydrogen Neuroprotection in Post-Ischemic Neurodegeneration in the Form of Alzheimer's Disease Proteinopathy: Underlying Mechanisms and Potential for Clinical Implementation-Fantasy or Reality? *Int J Mol Sci*, 2022, 23(12). [Crossref]
  47. Cole AR, Sperotto F, DiNardo JA, Carlisle S, Rivkin MJ, Sleeper LA, et al. Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults. *Crit Care Explor*, 2021, 3(10): e543. [Crossref]
  48. Toniolo S, Serra L, Olivito G, Caltagirone C, Mercuri NB, Marra C, et al. Cerebellar White Matter Disruption in Alzheimer's Disease Patients: A Diffusion Tensor Imaging Study. *J Alzheimers Dis*, 2020, 74(2): 615-624. [Crossref]
  49. Torso M, Bozzali M, Zamboni G, Jenkinson M, & Chance SA. Detection of Alzheimer's Disease using cortical diffusion tensor imaging. *Hum Brain Mapp*, 2021, 42(4): 967-977. [Crossref]
  50. Baird L, & Yamamoto M. The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway. *Mol Cell Biol*, 2020, 40(13). [Crossref]
  51. Bellezza I, Giambanco I, Minelli A, & Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. *Biochim Biophys Acta Mol Cell Res*, 2018, 1865(5): 721-733. [Crossref]
  52. Ma Q. Role of nrf2 in oxidative stress and toxicity. *Annu Rev Pharmacol Toxicol*, 2013, 53: 401-426. [Crossref]
  53. Taguchi K, & Yamamoto M. The KEAP1-NRF2 System as a Molecular Target of Cancer Treatment. *Cancers (Basel)*, 2020, 13(1). [Crossref]
  54. Saha S, Buttari B, Panieri E, Profumo E, & Saso L. An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation. *Molecules*, 2020, 25(22). [Crossref]
  55. Farina M, Vieira LE, Buttari B, Profumo E, & Saso L. The Nrf2 Pathway in Ischemic Stroke: A Review. *Molecules*, 2021, 26(16). [Crossref]
  56. Yu C, & Xiao JH. The Keap1-Nrf2 System: A Mediator between Oxidative Stress and Aging. *Oxid Med Cell Longev*, 2021, 2021: 6635460. [Crossref]
  57. Kawamura T, Wakabayashi N, Shigemura N, Huang CS, Masutani K, Tanaka Y, et al. Hydrogen gas reduces hyperoxic lung injury via the Nrf2 pathway in vivo. *Am J Physiol Lung Cell Mol Physiol*, 2013, 304(10): L646-656. [Crossref]
  58. Zhai X, Chen X, Shi J, Shi D, Ye Z, Liu W, et al. Lactulose ameliorates cerebral ischemia-reperfusion injury in rats by inducing hydrogen by activating Nrf2 expression. *Free Radic Biol Med*, 2013, 65: 731-741. [Crossref]
  59. Chen H, Xie K, Han H, Li Y, Liu L, Yang T, et al. Molecular hydrogen protects mice against polymicrobial sepsis by

- ameliorating endothelial dysfunction via an Nrf2/HO-1 signaling pathway. *Int Immunopharmacol*, 2015, 28(1): 643-654. [Crossref]
60. Yu J, Zhang W, Zhang R, Jiang G, Tang H, Ruan X, et al. Molecular hydrogen attenuates hypoxia/reoxygenation injury of intrahepatic cholangiocytes by activating Nrf2 expression. *Toxicol Lett*, 2015, 238(3): 11-19. [Crossref]
  61. Tamaki N, Orihuela-Campos RC, Fukui M, & Ito HO. Hydrogen-Rich Water Intake Accelerates Oral Palatal Wound Healing via Activation of the Nrf2/Antioxidant Defense Pathways in a Rat Model. *Oxid Med Cell Longev*, 2016, 2016: 5679040. [Crossref]
  62. Diao M, Zhang S, Wu L, Huan L, Huang F, Cui Y, et al. Hydrogen Gas Inhalation Attenuates Seawater Instillation-Induced Acute Lung Injury via the Nrf2 Pathway in Rabbits. *Inflammation*, 2016, 39(6): 2029-2039. [Crossref]
  63. Liu Y, Dong F, Guo R, Zhang Y, Qu X, Wu X, et al. Hydrogen-Rich Saline Ameliorates Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice Via the Nrf2-ARE Signaling Pathway. *Inflammation*, 2019, 42(2): 586-597. [Crossref]
  64. Yu Y, Yang Y, Yang M, Wang C, Xie K, & Yu Y. Hydrogen gas reduces HMGB1 release in lung tissues of septic mice in an Nrf2/HO-1-dependent pathway. *Int Immunopharmacol*, 2019, 69: 11-18. [Crossref]
  65. Lu Y, Li CF, Ping NN, Sun YY, Wang Z, Zhao GX, et al. Hydrogen-rich water alleviates cyclosporine A-induced nephrotoxicity via the Keap1/Nrf2 signaling pathway. *J Biochem Mol Toxicol*, 2020, 34(5): e22467. [Crossref]
  66. Xie K, Zhang Y, Wang Y, Meng X, Wang Y, Yu Y, et al. Hydrogen attenuates sepsis-associated encephalopathy by NRF2 mediated NLRP3 pathway inactivation. *Inflamm Res*, 2020, 69(7): 697-710. [Crossref]
  67. Yu Y, Feng J, Lian N, Yang M, Xie K, Wang G, et al. Hydrogen gas alleviates blood-brain barrier impairment and cognitive dysfunction of septic mice in an Nrf2-dependent pathway. *Int Immunopharmacol*, 2020, 85: 106585. [Crossref]
  68. Hu Y, Wang P, & Han K. Hydrogen Attenuated Inflammation Response and Oxidative in Hypoxic Ischemic Encephalopathy via Nrf2 Mediated the Inhibition of NLRP3 and NF- $\kappa$ B. *Neuroscience*, 2022, 485: 23-36. [Crossref]
  69. Peng J, He Q, Li S, Liu T, & Zhang J. Hydrogen-Rich Water Mitigates LPS-Induced Chronic Intestinal Inflammatory Response in Rats via Nrf-2 and NF- $\kappa$ B Signaling Pathways. *Vet Sci*, 2022, 9(11). [Crossref]
  70. Murakami Y, Ito M, & Ohsawa I. Molecular hydrogen protects against oxidative stress-induced SH-SY5Y neuroblastoma cell death through the process of mitohormesis. *PLoS One*, 2017, 12(5): e0176992. [Crossref]
  71. Yoshida A, Asanuma H, Sasaki H, Sanada S, Yamazaki S, Asano Y, et al. H<sub>2</sub> mediates cardioprotection via involvements of K(ATP) channels and permeability transition pores of mitochondria in dogs. *Cardiovasc Drugs Ther*, 2012, 26(3): 217-226. [Crossref]
  72. Jiao Y, Yu Y, Li B, Gu X, Xie K, Wang G, et al. Protective effects of hydrogen-rich saline against experimental diabetic peripheral neuropathy via activation of the mitochondrial ATP-sensitive potassium channel channels in rats. *Mol Med Rep*, 2020, 21(1): 282-290. [Crossref]
  73. Andrukhiv A, Costa AD, West IC, & Garlid KD. Opening mitoKATP increases superoxide generation from complex I of the electron transport chain. *Am J Physiol Heart Circ Physiol*, 2006, 291(5): H2067-2074. [Crossref]
  74. Jin Z, Zhao P, Gong W, Ding W, He Q. Fe-porphyrin: A redox-related biosensor of hydrogen molecule. *Nano Research*, 2022, 16 (2): 2020-2025. [Crossref]
  75. Green D, & Ts'ao CH. Hematin: effects on hemostasis. *J Lab Clin Med*, 1990, 115(2): 144-147.
  76. Siebert SW, & Holt RJ. Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: a literature review. *Adv Ther*, 2008, 25(9): 842-857. [Crossref]
  77. Gunsalus IC, Sligar SG, Nordlund T, Frauenfelder H. Oxygen sensing heme proteins: monooxygenases, myoglobin and hemoglobin. *Adv Exp Med Bio.* 1977, 78: 37-50. [Crossref]
  78. Nagababu E, & Rifkind JM. Heme degradation by reactive oxygen species. *Antioxid Redox Signal*, 2004, 6(6): 967-978. [Crossref]
  79. Liu Y, Zhao Y, & Wang J. Fenton/Fenton-like processes with in-situ production of hydrogen peroxide/hydroxyl radical for degradation of emerging contaminants: Advances and prospects. *J Hazard Mater*, 2021, 404(Pt B): 124191. [Crossref]
  80. Liochev SL. The role of iron-sulfur clusters in in vivo hydroxyl radical production. *Free Radic Res*, 1996, 25(5): 369-384. [Crossref]
  81. Piel RB, 3rd, Dailey HA, Jr, & Medlock AE. The mitochondrial heme metabolon: Insights into the complex(ity) of heme synthesis and distribution. *Mol Genet Metab*, 2019, 128(3): 198-203. [Crossref]
  82. Umezawa N, Matsumoto N, Iwama S, Kato N, & Higuchi T. Facile synthesis of peptide-porphyrin conjugates: Towards artificial catalase. *Bioorg Med Chem*, 2010, 18(17): 6340-6350. [Crossref]
  83. Damos FS, Sotomayor Mdel P, Kubota LT, Tanaka SM, & Tanaka AA. Iron(III) tetra-(N-methyl-4-pyridyl)-porphyrin as a biomimetic catalyst of horseradish peroxidase on the electrode surface: an amperometric sensor for phenolic compound determinations. *Analyst*, 2003, 128(3): 255-259. [Crossref]
  84. Watanabe Y. Alternatives to the oxoferryl porphyrin cation radical as the proposed reactive intermediate of cytochrome P450: two-electron oxidized Fe(III) porphyrin derivatives. *J Biol Inorg Chem*, 2001, 6(8): 846-856. [Crossref]
  85. Pfeiffer S, Schrammel A, Koesling D, Schmidt K, & Mayer B. Molecular actions of a Mn(III)Porphyrin superoxide dismutase mimetic and peroxynitrite scavenger: reaction with nitric oxide and direct inhibition of NO synthase and soluble guanylyl cyclase. *Mol Pharmacol*, 1998, 53(4): 795-800. [Crossref]
  86. Di Venosa G, Battle A, Fukuda H, MacRobert A, & Casas A. Distribution of 5-aminolevulinic acid derivatives and induced porphyrin kinetics in mice tissues. *Cancer Chemother Pharmacol*, 2006, 58(4): 478-486. [Crossref]
  87. Bohle DS, & Helms JB. Synthesis of beta-hematin by de-

- hydrohalogenation of hemin. *Biochem Biophys Res Commun*, 1993, 193(2): 504-508. [[Crossref](#)]
88. Grenoble DC, & Drickamer HG. The effect of pressure on the oxidation state of iron. 3. Hemin and hematin. *Proc Natl Acad Sci U S A*, 1968, 61(4): 1177-1182. [[Crossref](#)]
89. Kim YC, Masutani H, Yamaguchi Y, Itoh K, Yamamoto M, & Yodoi J. Hemin-induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. *J Biol Chem*, 2001, 276(21): 18399-18406. [[Crossref](#)]
90. Nagai T, Kikuchi S, Ohmine K, Miyoshi T, Nakamura M, Kondo T, *et al.* Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2. *J Cell Biochem*, 2008, 104(2): 680-691. [[Crossref](#)]
91. Georgiou-Siafis SK, & Tsiftoglou AS. Activation of KEAP1/NRF2 stress signaling involved in the molecular basis of hemin-induced cytotoxicity in human proerythroid K562 cells. *Biochem Pharmacol*, 2020, 175: 113900. [[Crossref](#)]
92. Mattson MP. Hormesis defined. *Ageing Res Rev*, 2008, 7(1): 1-7. [[Crossref](#)]
93. Li X, Yang T, & Sun Z. Hormesis in Health and Chronic Diseases. *Trends Endocrinol Metab*, 2019, 30(12): 944-958. [[Crossref](#)]

**Cite this article as:** Ohta SG. Molecular hydrogen may activate the transcription factor Nrf2 to alleviate oxidative stress through the hydrogen-targeted porphyrin. *Ageing Pathobiol Ther*, 2023, 5(1): 25-32. doi: 10.31491/APT.2023.03.104

## Aging Pathobiology and Therapeutics

### ABOUT

---

#### AIMS AND SCOPE

Aging Pathobiology and Therapeutics (APT) is an open access, peer-reviewed, interdisciplinary journal available online, committed to disseminating information on the pathological progression and intervention of aging and age-related disease phenotypes in mammalian species, providing an opportunity to communicate pathology data as a primary scientific focus of aging. Scholars from the disciplines of geriatrics, gerontology, physiology, pathology, pharmacology, toxicology, biology, neuropsychology, psychology, nursing, epidemiology, and genetics are encouraged to contribute articles to the journal. Article types considered include research articles, reviews, editorials, case reports, opinions, letters, abstracts and drug therapeutic brief relating to research on Aging.

The Editorial Board of the Journal comprises a dedicated team of local and international experts in the field of geriatrics, gerontology, physiology, pathology, pharmacology, biology, neuropsychology, psychology, nursing, epidemiology, and genetics. All members of the Editorial Board actively guide and set the direction of the journal. With the aim of promoting effective and accurate scientific information, an expert panel of referees constitutes the backbone of the peer-review process in evaluating the quality and content of manuscripts submitted for publication.

---

#### INFORMATION FOR AUTHORS

APT follows the Committee on Publication Ethics (COPE)'s guidelines and the ICMJE recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journal.

Manuscripts submitted must be the original work of the author(s) and must not be published previously or under consideration for publication elsewhere.

---

#### JOURNAL INFORMATION

- Official Publication: Geropathology Research Network, Geriatric Department of Guangzhou First People's Hospital (CN)



- Funded: APT is funded by ANT Publishing Corporation
- Ownership: APT is owned by Geropathology Research Network and published by ANT Publishing Corporation

---

### JOURNAL STATISTICS

- Launch date: 11 November 2019
- Publication model: Open access
- ISSN: 2690-1803 (Online)
- Digital archive: Portico
- Frequency: Quarterly published
- DOI: 10.31491/APT

---

### SUBMISSION TURNAROUND TIME

- Initial review: 3 days
- External peer review: 2–3 weeks
- Publication ahead of print: within 2 weeks after being accepted
- Formal publication: within 1-2 months after being accepted

---

### INDEXING / ABSTRACTING

- Scopus
- Chemical Abstracts Service
- CNKI Scholar
- Google Scholar
- ICI World of Journals
- Portico
- Research Gate
- Scilit

- Semantic Scholar
- Sherpa/Romeo
- ScienceOpen
- WorldCat

---

#### COPYRIGHT AND LICENSE TO PUBLISH

APT is a peer reviewed, open access journal. All content of the journal is published under the Creative Commons Attribution 4.0 International (CC BY 4.0). The CC BY 4.0 allows for maximum dissemination and re-use of open access materials and is preferred by many research funding bodies. Under this license users are free to share (copy, distribute and transmit) and remix (adapt) the contribution for any purposes, even commercially, provided that the users appropriately acknowledge the original authors and the source. Copyright is retained by authors. Authors are required to sign a Submission Statement (which can be downloaded from the journal's Author Guidelines), which identifies itself as the original publisher, exclusive rights to publish their articles, and granting any third party the right to use the articles freely as long as the integrity is maintained and the original authors, citation details and publisher are identified.

---

#### EDITORIAL OFFICE

- Email: [apt@antpublisher.com](mailto:apt@antpublisher.com)
- US Office: 2879 Tynewick Dr, Roswell, Georgia, 30075, USA
- China Office: Room 1006, Wuxing Building, No. 280-1 Tongyang Road, Liangxi District, Wuxi, China

## ANT Publishing

### ABOUT

Headquartered in Georgia, USA, ANT Publishing Corporation is a scholarly open access and peer-reviewed publisher specializing in the publication of biomedical journals in print and online across the broad spectrum of science, technology and medicine. ANT possesses standard publication ethics, a rigorous peer review process, and rapid publication, aiming to provide a significant contribution to the academic exchange. All journals published by ANT currently working towards being indexed in PubMed, Science Citation Index Expanded (SCIE), BIOSIS, Scopus. We strive to provide an easily and freely accessible platform to researchers and practitioners in support of their novel and valuable ideas. Currently, we are concentrating on building the following journals.

AGING PATHOBIOLOGY AND THERAPEUTICS

URO-TECHNOLOGY JOURNAL

ANIMAL HEALTH AND THERAPY REPORTS

All ANT journals are international, peer-reviewed Open Access journals. In accordance with our Open Access policy (under the Creative Commons Attribution (CC BY 4.0) License), all papers, including supplements, published in ANT journals are immediately and permanently available online, and free to access, distribute, and reuse provided that the original work is correctly cited. For more details, please see our Open Access Policies.

All ANT journals maintain a rigorous, thorough, unbiased peer review. Besides, quality control is imbedded in each step of the editorial process, and in each internal and external editors' responsibilities. In this quality control system, all editors abide by the procedures, standards and ethical polices outlined by the Committee on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE), the Open Access Scholarly Publishers Association (OASPA), the World Association of Medical Editors (WAME) and Directory of Open Access Journals (DOAJ). More details regarding ANT peer review and quality control system are introduced in Editorial Process.

## CONTACT US

- Website: <http://www.antpublisher.com>
- Tel: +1(513)291-3698
- US Office: 2879 Tynewick Dr, Roswell, Georgia, 30075, USA
- China Office: Room 1006, Wuxing Building, No. 280-1 Tongyang Road, Liangxi District, Wuxi, China
- General editorial enquiries: [editorialoffice@antpublisher.com](mailto:editorialoffice@antpublisher.com)
- Cooperation enquiries: [support@antpublisher.com](mailto:support@antpublisher.com)
- Copyright related enquiries: [service@antpublisher.com](mailto:service@antpublisher.com)